[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 304
61. Laney AS, Cannon MJ, Jaffe HW, Offermann MK, Ou CY, Radford KW, Patel MM, Spira TJ, Gunthel CJ, Pellett PE, Dollard SC: Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma. AIDS; 2007 Jul 31;21(12):1541-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma.
  • OBJECTIVE: We present the largest longitudinal study to date that examines the association between Kaposi's Sarcoma (KS) disease progression and the presence and viral load of human herpesvirus 8 (HHV-8).
  • METHODS: Ninety-six men were enrolled at HIV clinics in Atlanta, Georgia, who had KS (n = 47) or were without KS but seropositive for HHV-8.
  • Visits occurred at 6-month intervals for 2 years at which the patient's KS status was evaluated and oral fluid and blood were collected for quantification of HHV-8 DNA and antibodies.
  • RESULTS: The presence of HHV-8 DNA in blood was more common (P < 0.001) and the viral load higher (P < 0.001) in men with KS in comparison with men without KS.
  • Mean HHV-8 viral loads in blood and oral fluids were associated with disease status, being highest among patients with progressing KS, intermediate among patients with stable KS, and lowest among patients with regressing KS.
  • Consistent with our previous report high antibody titers to HHV-8 orf 65 were inversely associated with HHV-8 shedding in oral fluid.
  • CONCLUSIONS: We observed a significant association between changes in KS disease severity and the presence and viral load of HHV-8.
  • HHV-8 viral load in blood may provide useful information to clinicians for assessment of the risk of further disease progression in patients with KS.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Herpesvirus 8, Human / isolation & purification. Sarcoma, Kaposi / virology. Viral Load
  • [MeSH-minor] Antibodies, Viral / blood. Disease Progression. Follow-Up Studies. Humans. Leukocytes, Mononuclear / virology. Male. Saliva / virology. Severity of Illness Index. Virus Shedding


62. Pyakurel P, Montag U, Castaños-Vélez E, Kaaya E, Christensson B, Tönnies H, Biberfeld P, Heiden T: CGH of microdissected Kaposi's sarcoma lesions reveals recurrent loss of chromosome Y in early and additional chromosomal changes in late tumour stages. AIDS; 2006 Sep 11;20(14):1805-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CGH of microdissected Kaposi's sarcoma lesions reveals recurrent loss of chromosome Y in early and additional chromosomal changes in late tumour stages.
  • BACKGROUND: It is still unclear if Kaposi's sarcoma (KS) is a monoclonal cell proliferation or a polyclonal, hyperplastic, reactive process.
  • Reports on KS cytogenetics are few and restricted to late stage disease and cell lines.
  • METHOD: We analysed 27 KS, early and late, AIDS related (AKS) and endemic (EKS) by laser microdissection, global DNA amplification and comparative genomic hybridization (CGH).
  • RESULT: Loss of Y chromosome was detected in 20/23 male KS, which was the only recurrent chromosomal aberration in all nine male early (patch) KS.
  • CONCLUSION: Clonal loss of chromosome Y was detected in all early male KS, while additional chromosomal aberrations appeared during development to late KS.
  • This increase in chromosomal abnormalities during tumour growth indicates genetic instability and the selection of survival cell clones establishing late, aggressive sarcoma growth.
  • Our data support the view that KS (in males) develops into a clonal tumour yet initially is a hyperplastic reactive cell proliferation.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Y / genetics. Nucleic Acid Hybridization / methods. Sarcoma, Kaposi / genetics
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / genetics. Chromosomes, Human, X / genetics. DNA, Neoplasm / genetics. Female. Herpesvirus 8, Human / genetics. Humans. In Situ Hybridization, Fluorescence / methods. Male. Microdissection / methods. Neoplasm Staging. Nucleic Acid Amplification Techniques / methods

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954721.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


63. Iregbu KC, Elegba OY: Prevalence of Kaposi's sarcoma among adult HIV-seropositive patients seen in a designated HIV treatment and care center in Abuja, Nigeria. J Int Assoc Physicians AIDS Care (Chic); 2006 Sep;5(3):115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of Kaposi's sarcoma among adult HIV-seropositive patients seen in a designated HIV treatment and care center in Abuja, Nigeria.
  • BACKGROUND: There is a dearth of information on the prevalence of AIDS-associated Kaposi's sarcoma (AAKS) in Nigeria despite the HIV National seroprevalence of 5% and the occurrence of the disease in people living with HIV/AIDS.
  • OBJECTIVE: To determine the prevalence of AAKS among HIV-seropositive adults seen in an HIV/AIDS treatment and care center in Abuja, Nigeria.
  • METHOD: Medical records of the 1591 patients comprising 857 males and 734 females were reviewed, and relevant data such as age, sex, CD4 count at diagnosis of AAKS were obtained and analyzed.
  • CONCLUSION: Easy access to antiretroviral medications and a well-targeted education and awareness campaign will help reduce the incidence and prevalence of the disease.
  • The inability to perform histologic examinations on all suspected cases calls for a well-designed prospective study to determine the actual prevalence of Kaposi's sarcoma in HIV-seropositive patients in Nigeria.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Acquired Immunodeficiency Syndrome / epidemiology. HIV Seropositivity / epidemiology. Sarcoma, Kaposi / epidemiology


6
Advertisement
4. Bottler T, Kuttenberger J, Hardt N, Oehen HP, Baltensperger M: Non-HIV-associated Kaposi's sarcoma of the tongue. Case report and review of the literature. Int J Oral Maxillofac Surg; 2007 Dec;36(12):1218-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-HIV-associated Kaposi's sarcoma of the tongue. Case report and review of the literature.
  • Kaposi's sarcoma is a frequently seen AIDS-related malignant neoplasm in the head and neck region, especially in the oral cavity, but is rarely described in the HIV-negative and non-immunosuppressed individual.
  • The case of a 76-year-old HIV-negative, non-immunocompromised woman with a solitary Kaposi's sarcoma of the tongue is reported.
  • Diagnosis and therapy are discussed and compared with a review of the contemporary literature.
  • [MeSH-major] HIV Seronegativity. Immunocompetence. Sarcoma, Kaposi / pathology. Tongue Neoplasms / pathology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614259.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 20
  •  go-up   go-down


65. Burnside KL, Ryan JT, Bielefeldt-Ohmann H, Gregory Bruce A, Thouless ME, Tsai CC, Rose TM: RFHVMn ORF73 is structurally related to the KSHV ORF73 latency-associated nuclear antigen (LANA) and is expressed in retroperitoneal fibromatosis (RF) tumor cells. Virology; 2006 Oct 10;354(1):103-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RFHVMn ORF73 is structurally related to the KSHV ORF73 latency-associated nuclear antigen (LANA) and is expressed in retroperitoneal fibromatosis (RF) tumor cells.
  • Retroperitoneal fibromatosis herpesvirus (RFHV), the macaque homolog of the human rhadinovirus, Kaposi's sarcoma-associated herpesvirus (KSHV), was first identified in retroperitoneal fibromatosis (RF) tumor lesions of macaques with simian AIDS.
  • We cloned and sequenced the ORF73 latency-associated nuclear antigen (LANA) of RFHVMn from the pig-tailed macaque.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879850.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / DE07023; United States / NIAID NIH HHS / AI / K02 AI49275; United States / NCRR NIH HHS / RR / RR13154
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Viral; 0 / DNA, Viral; 0 / Nuclear Proteins; 0 / latency-associated nuclear antigen
  •  go-up   go-down


66. Little RF, Aleman K, Kumar P, Wyvill KM, Pluda JM, Read-Connole E, Wang V, Pittaluga S, Catanzaro AT, Steinberg SM, Yarchoan R: Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood; 2007 Dec 15;110(13):4165-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma.
  • Thirty-six patients with AIDS-associated Kaposi sarcoma (KS) requiring chemotherapy were treated for six 3-week cycles of pegylated liposomal doxorubicin (20 mg/m(2)) plus interleukin-12 (IL-12; 300 ng/kg subcutaneously twice weekly), followed by 500 ng/kg subcutaneous IL-12 twice weekly for up to 3 years.
  • Twenty-two had poor-prognosis KS (T(1)S(1)).
  • Of 27 patients with residual disease when starting maintenance IL-12, 15 had a new major response compared with this new baseline.
  • The regimen of IL-12 plus liposomal doxorubicin yielded rapid tumor responses and a high response rate in patients with AIDS-KS receiving HAART, and responses were sustained on IL-12 maintenance therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Doxorubicin / analogs & derivatives. Interleukin-12 / administration & dosage. Polyethylene Glycols / administration & dosage. Sarcoma, Kaposi / drug therapy
  • [MeSH-minor] AIDS-Related Opportunistic Infections / drug therapy. Adult. Antiretroviral Therapy, Highly Active. Chemokine CXCL10 / blood. Drug Therapy, Combination. Humans. Interferon-gamma / blood. Middle Aged. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 2000 Jan;119(1):28-37 [10606961.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):405-8 [9670053.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4873-80 [10987301.001]
  • [Cites] J Infect Dis. 2001 Apr 1;183(7):1116-20 [11237839.001]
  • [Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]
  • [Cites] HIV Clin Trials. 2001 Sep-Oct;2(5):429-37 [11673818.001]
  • [Cites] J Invest Dermatol. 2001 Oct;117(4):858-63 [11676823.001]
  • [Cites] AIDS. 2002 May 24;16(8):1147-54 [12004273.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10 [12189223.001]
  • [Cites] J Infect Dis. 2003 Jan 1;187(1):149-53 [12508160.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):76-83 [12538454.001]
  • [Cites] AIDS. 2004 Aug 20;18(12):1737-40 [15280789.001]
  • [Cites] Technol Cancer Res Treat. 2004 Oct;3(5):451-7 [15453810.001]
  • [Cites] N Engl J Med. 1985 Jul 11;313(2):79-84 [2582258.001]
  • [Cites] J Biol Response Mod. 1985 Aug;4(4):358-64 [3928825.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Exp Med. 1989 Sep 1;170(3):827-45 [2504877.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1201-7 [2671281.001]
  • [Cites] Immunol Today. 1991 Oct;12(10):346-8 [1683536.001]
  • [Cites] Am J Epidemiol. 1993 Aug 15;138(4):266-78 [8356967.001]
  • [Cites] J Exp Med. 1993 Oct 1;178(4):1223-30 [8104230.001]
  • [Cites] Blood. 1993 Nov 1;82(9):2790-6 [8106018.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1993;5(6):367-71 [8305357.001]
  • [Cites] J Acquir Immune Defic Syndr. 1994 May;7(5):463-8 [8158540.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2101-6 [10070318.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1905-17 [10430098.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):990-8 [15598977.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):293-9 [15980688.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):779-85 [16077928.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):406-15; quiz 423 [16130937.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4650-7 [16507779.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2876-82 [12885804.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):399-402 [14752065.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] J Immunol. 1994 Aug 15;153(4):1697-706 [7913943.001]
  • [Cites] Blood. 1994 Dec 15;84(12):4008-27 [7994020.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Blood. 1996 May 1;87(9):3877-82 [8611715.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;38(2):169-77 [8616908.001]
  • [Cites] J Leukoc Biol. 1996 May;59(5):623-30 [8656046.001]
  • [Cites] J Virol. 1996 Nov;70(11):8218-23 [8892957.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2635-43 [9108380.001]
  • [Cites] J Immunol. 1997 May 15;158(10):4992-5001 [9144519.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3085-92 [9294471.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(6):497-504 [9554595.001]
  • [Cites] AIDS. 2000 May 26;14(8):987-93 [10853980.001]
  • (PMID = 17846226.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00020449
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL10 protein, human; 0 / Chemokine CXCL10; 0 / liposomal doxorubicin; 187348-17-0 / Interleukin-12; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2234790
  •  go-up   go-down


67. Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, Di Trolio R, De Placido S, Dezube BJ: Management of AIDS-related Kaposi's sarcoma. Lancet Oncol; 2007 Feb;8(2):167-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of AIDS-related Kaposi's sarcoma.
  • The advent of highly active antiretroviral therapy (HAART) has lead to a substantial reduction in the prevalence, morbidity, and mortality associated with AIDS-related Kaposi's sarcoma.
  • Similarly, concomitant advances in chemotherapy and supportive-care protocols have allowed for Kaposi's sarcoma to be managed more effectively in comparison with the pre-HAART era.
  • Furthermore, developments in our understanding of the pathogenesis of Kaposi's sarcoma have identified several molecular targets that can potentially provide new therapeutic strategies.
  • This Review discusses the role of conventional chemotherapeutic and immunomodulatory agents in the treatment of Kaposi's sarcoma and summarises the current status and future prospects of novel molecularly targeted agents in the treatment of this disease.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Sarcoma, Kaposi / drug therapy


68. Venkatarajan S, Glaich AS, Ostler DA, Hsu S: A case of Kaposi sarcoma mimicking nephrogenic systemic fibrosis. Dermatol Online J; 2009;15(12):6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Kaposi sarcoma mimicking nephrogenic systemic fibrosis.
  • Kaposi sarcoma is a neoplasm commonly seen in HIV patients.
  • In AIDS-associated Kaposi sarcoma, small red papules or nodules initially present on the face, especially on the nose, and the trunk, that then rapidly spread to other areas.
  • We present an unusual case of AIDS-associated Kaposi sarcoma mimicking nephrogenic systemic fibrosis.
  • [MeSH-major] Nephrogenic Fibrosing Dermopathy / pathology. Sarcoma, Kaposi / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male


69. Bihl F, Mosam A, Henry LN, Chisholm JV 3rd, Dollard S, Gumbi P, Cassol E, Page T, Mueller N, Kiepiela P, Martin JN, Coovadia HM, Scadden DT, Brander C: Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS; 2007 Jun 19;21(10):1245-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
  • BACKGROUND: Kaposi's sarcoma-associated herpesvirus (KSHV) is endemic in South Africa and the clinical manifestation of AIDS-associated Kaposi's sarcoma (KS) represents a significant clinical problem.
  • Whereas the positive effects of HAART on the regression of KS have been well established, less is known about the role of herpesvirus-specific cellular immunity in disease improvement.
  • DESIGN: Thirty-three treatment-naive HIV clade C-infected individuals with KS were randomly assigned into two treatment arms (HAART plus systemic chemotherapy versus HAART alone).
  • KSHV-specific cellular immune responses, viral loads and clinical outcome were evaluated.
  • METHODS: KSHV, Epstein-Barr virus and HIV-specific cellular immunity was measured using an IFN-gamma enzyme-linked immunospot assay in samples obtained at baseline and up to 11 months after treatment initiation.
  • Cell-associated KSHV viremia was determined by real-time polymerase chain reaction.
  • RESULTS: Robust increases in CD4 cell counts and suppressed HIV viral loads were seen in parallel with significant increases in the KSHV-specific cellular immune responses over time.
  • CONCLUSION: The data show a temporal association between the clinical improvement of KS and the re-appearance of KSHV-specific cellular immunity, and demonstrate an effective suppression of KSHV viral replication using combination therapy.
  • [MeSH-major] HIV Infections / drug therapy. Herpesvirus 8, Human / immunology. Sarcoma, Kaposi / drug therapy
  • [MeSH-minor] AIDS-Related Opportunistic Infections / drug therapy. AIDS-Related Opportunistic Infections / immunology. AIDS-Related Opportunistic Infections / virology. Adult. Antiretroviral Therapy, Highly Active / methods. CD4 Lymphocyte Count. Female. Humans. Immunity, Cellular / drug effects. Immunity, Cellular / immunology. Male. Middle Aged. T-Lymphocytes, Cytotoxic / immunology. Treatment Outcome. Viral Load. Viremia / immunology. Virus Replication / drug effects. Virus Replication / immunology


70. Schlossbauer T, Schmidt GP, Bogner JR, Sing A, Reiser MF, Becker-Gaab C: Pulmonary radiological characteristics in patients with HIV infection at the time of highly active antiretroviral therapy (HAART). Eur J Med Res; 2007 Aug 16;12(8):341-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary radiological characteristics in patients with HIV infection at the time of highly active antiretroviral therapy (HAART).
  • OBJECTIVE: To report on radiological and epidemiological characteristics of pulmonary disease in patients with HIV infection in times of highly active antiretroviral therapy (HAART).
  • METHODS: Clinical data of 130 HIV infected adults with acute pulmonary symptoms were compared with findings in chest radiography (n = 130) and computed tomography (CT, n = 42).
  • Disease specific sensitivity was 0.33 compared to 0.70.
  • Bacterial pneumonia (BP, n = 26, 20%) was the most frequent diagnosis, followed by pneumocystis jiroveci pneumonia (PJP, n = 17, 13%), mycobacterium avium complex (MAC, 6%), Kaposi's sarcoma and lymphoma (KS and NHL, each 4%), fungal pneumonia (2%), and tuberculosis (TBC, 1%).
  • Only contrast-enhanced computed tomography shows an acceptable disease-specific sensitivity.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Acquired Immunodeficiency Syndrome / radiography. Antiretroviral Therapy, Highly Active. Lung Diseases / radiography. Radiography, Thoracic. Tomography, X-Ray Computed / methods


71. Albini A, Brigati C, Ventura A, Lorusso G, Pinter M, Morini M, Mancino A, Sica A, Noonan DM: Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med; 2009;7:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target.
  • We had previously demonstrated that innate immune cells are key targets of angiostatin, however the pathway involved in this immune-related angiogenesis inhibition was not known.
  • RESULTS: Angiostatin inhibts angiogenesis induced by VEGF-TNFalpha or supernatants of Kaposi's Sarcoma cells (a highly angiogenic and inflammation-associated tumor).
  • CONCLUSION: Our data demonstrate that an endogenous angiogenesis inhibitor such as angiostatin act on innate immune cells as key targets in inflammatory angiogenesis.
  • Angiostatin proves to be anti-angiogenic as an immune modulator rather than a direct anti-vascular agent.
  • [MeSH-major] Angiogenesis Inhibitors / immunology. Angiostatins / immunology. Immune System / immunology. Immunity, Innate / immunology. Interleukin-12 / immunology

  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 2007 Oct;213(1):27-35 [17450519.001]
  • [Cites] Nat Biotechnol. 2007 Aug;25(8):911-20 [17664940.001]
  • [Cites] Genes Dev. 2007 Aug 15;21(16):2055-68 [17699752.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):825-31 [18064003.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):618-31 [18633355.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):3609-19 [18714035.001]
  • [Cites] Eur Heart J. 2008 Oct;29(19):2325-6 [18762551.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5875-7 [10606226.001]
  • [Cites] Int J Mol Med. 2000 May;5(5):547-51 [10762660.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10229-33 [11150311.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6656-61 [11381144.001]
  • [Cites] FASEB J. 2002 Feb;16(2):267-9 [11772950.001]
  • [Cites] J Mol Biol. 2002 May 10;318(4):1009-17 [12054798.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):87-91 [12469189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4736-41 [12682294.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45826-32 [12954626.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6020-9 [14676128.001]
  • [Cites] Gene Ther. 2004 Feb;11(3):284-91 [14737088.001]
  • [Cites] Recent Prog Horm Res. 2004;59:73-104 [14749498.001]
  • [Cites] J Immunol. 1994 Jul 1;153(1):128-36 [7911493.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] AIDS. 1994 Sep;8(9):1237-44 [7528513.001]
  • [Cites] Nat Med. 1996 Jun;2(6):689-92 [8640562.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14002-7 [8943050.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13153-8 [9789057.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2041-8 [10479644.001]
  • [Cites] J Biol Chem. 1999 Oct 8;274(41):29568-71 [10506224.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1036-43 [15383457.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2042-6 [15840902.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4610-9 [15958647.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8359-65 [16166313.001]
  • [Cites] J Cell Biochem. 2005 Oct 1;96(2):242-61 [16094651.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10637-41 [16322203.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] J Invest Dermatol. 2007 Jan;127(1):65-74 [16888632.001]
  • (PMID = 19144161.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Chemokine CCL2; 0 / Interleukin-8; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; 187348-17-0 / Interleukin-12; 86090-08-6 / Angiostatins
  • [Other-IDs] NLM/ PMC2630934
  •  go-up   go-down


72. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I: Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm; 2005 Jan;59(1):177-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.
  • Taxol is a marketed product for the treatment of ovarian, breast, non-small cell lung cancer and AIDS-related Kaposi's Sarcoma.
  • However, paclitaxel is only sparingly soluble in water and therefore, intravenous administration depends on the use of the non-ionic surfactant Cremophor EL (polyethoxylated castor oil) to achieve a clinically relevant concentrated solution.
  • Unfortunately, Cremophor EL increases toxicity and leads to hypersensitivity reactions in certain individuals.

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. GLYCERIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15567316.001).
  • [ISSN] 0939-6411
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Liposomes; 0 / Pharmaceutical Vehicles; 0 / Solvents; 6D4M1DAL6O / cremophor EL; P88XT4IS4D / Paclitaxel; PDC6A3C0OX / Glycerol
  •  go-up   go-down


73. Pantanowitz L, Dezube BJ, Hernandez-Barrantes S, Tahan SR, Dabbous MK: Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma. J Cutan Pathol; 2006 Dec;33(12):793-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma.
  • BACKGROUND: Matrix metalloproteinases (MMPs) are associated with Kaposi's sarcoma (KS) tumorigenesis.
  • To date, only a few MMPs have been studied in KS lesions.
  • Their role in KS regression has not been investigated.
  • The aim of this study was to evaluate the expression of multiple MMPs in developing and pharmacologically regressed KS lesions.
  • METHODS: Nine samples of acquired immune deficiency syndrome (AIDS)-related and classic cutaneous KS lesions at various histological stages were studied.
  • Regressing KS lesions from three patients treated with systemic therapy were procured after one and two cycles of chemotherapy.
  • RESULTS: KS lesional cells were immunoreactive for all MMPs, except MMP-14.
  • The MMP immunoprofile in residual KS lesional cells was unaltered in regressed lesions.
  • CONCLUSIONS: These data show that developing KS lesional cells express collagenases (MMP-1, MMP-13), gelatinases (MMP-2, MMP-9), stromelysin-1 (MMP-3), and matrilysin (MMP-7) but not the membrane-type MMP-14.
  • This MMP expression profile is retained by residual KS cells and also expressed by infiltrating macrophages in regressed KS lesions.
  • Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Matrix Metalloproteinases / metabolism. Sarcoma, Kaposi / enzymology. Sarcoma, Kaposi / pathology
  • [MeSH-minor] Disease Progression. Humans. Immunohistochemistry. Male. Middle Aged


74. Taiwo OO, Okeke EN, Jalo PH, Danfillo IS: Oral manifestation of HIV/AIDS in Plateau state indigenes, Nigeria. West Afr J Med; 2006 Jan-Mar;25(1):32-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral manifestation of HIV/AIDS in Plateau state indigenes, Nigeria.
  • BACKGROUND: To investigate the prevalence of oral manifestations of HIV/AIDS involving HIV positive Plateau State indigenous adults attending a Special Treatment Clinic serving referred cases and in-patient cases hospitalized in the Medical wards in JUTH, Jos.
  • RESULTS: A total of 261 patients confirmed for HIV infection were examined.
  • Oral lesions attributable to HIV/ AIDS infection were found in 109 (41.8%) patients, 38 (34.9%) of these patients had multiple lesions.
  • Kaposi's Sarcoma was in 5 (1.9%) patients.
  • CONCLUSION: The prevalence of HIV-related oral lesions (HIV-ROL) in a hospital based adult population of Plateau State indigenes in Jos is 41.8%.
  • Oral Candidiasis is the most common HIV-ROL detected and this agrees with most reported findings.
  • [MeSH-major] HIV Infections / epidemiology. Mouth Diseases / diagnosis. Mouth Diseases / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Causality. Cross-Sectional Studies. Disease Transmission, Infectious / statistics & numerical data. Female. Humans. Male. Middle Aged. Nigeria / epidemiology. Prevalence. Sex Distribution. Sexual Behavior / statistics & numerical data. Substance Abuse, Intravenous / epidemiology


75. Dougan S, Evans BG, Macdonald N, Goldberg DJ, Gill ON, Fenton KA, Elford J: HIV in gay and bisexual men in the United Kingdom: 25 years of public health surveillance. Epidemiol Infect; 2008 Feb;136(2):145-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV in gay and bisexual men in the United Kingdom: 25 years of public health surveillance.
  • It is more than 25 years since the first case of AIDS was reported in the United Kingdom.
  • National surveillance began the following year, in September 1982, with the notification of deaths and clinical reports of AIDS and Kaposi's sarcoma plus laboratory reports of opportunistic infections.
  • The introduction of the HIV antibody test in 1984 led to the reporting of HIV-positive tests by laboratories and the establishment of an unlinked anonymous survey in 1990 measuring undiagnosed HIV infection among gay men attending sexual health clinics.
  • The widespread use of highly active antiretroviral therapies (HAART) since 1996 has averted many deaths among HIV-positive gay men and has also resulted in a large reduction in AIDS cases.
  • This led to a need for an enumeration of gay men with HIV accessing NHS treatment and care services (1995 onwards), more clinical information on HIV diagnoses for epidemiological surveillance (2000 onwards) and the routine monitoring of drug resistance (2001 onwards).
  • Twenty-five years after the first case of AIDS was reported, gay and bisexual men remain the group at greatest risk of acquiring HIV in the United Kingdom.
  • Latest estimates suggest that in 2004, 26 500 gay and bisexual men were living with HIV in the United Kingdom, a quarter of whom were undiagnosed.
  • In this review, we examine how national surveillance systems have evolved over the past 25 years in response to the changing epidemiology of HIV/AIDS among gay and bisexual men in the United Kingdom as well as advances in laboratory techniques and medical treatments.
  • [MeSH-major] Bisexuality. HIV Infections / epidemiology. HIV Infections / history. Homosexuality, Male. Population Surveillance / methods

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Gay, Lesbian, Bisexual, and Transgender Health.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 1995 Aug 26;311(7004):545 [7663211.001]
  • [Cites] AIDS. 2002 Jul 5;16(10):F19-24 [12131206.001]
  • [Cites] Genitourin Med. 1997 Oct;73(5):348-54 [9534742.001]
  • [Cites] JAMA. 1998 Jul 1;280(1):42-8 [9660362.001]
  • [Cites] Sex Transm Infect. 1998 Jun;74(3):185-8 [9849553.001]
  • [Cites] AIDS. 1999 Jan 14;13(1):103-8 [10207551.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 15;21(5):401-7 [10458621.001]
  • [Cites] AIDS. 1999 Aug 20;13(12):1535-41 [10465078.001]
  • [Cites] N Engl J Med. 1963 Jan 24;268:182-92 [13928666.001]
  • [Cites] Sex Transm Infect. 2004 Dec;80(6):451-4 [15572612.001]
  • [Cites] Sex Transm Infect. 2004 Dec;80(6):492-7 [15572622.001]
  • [Cites] AIDS. 2005 Mar 25;19(5):513-20 [15764857.001]
  • [Cites] AIDS. 2002 Aug 16;16(12):1663-71 [12172088.001]
  • [Cites] AIDS. 2004 Jan 23;18(2):265-72 [15075544.001]
  • [Cites] AIDS. 2004 Mar 26;18(5):834-5 [15075529.001]
  • [Cites] Commun Dis Public Health. 2004 Mar;7(1):11-4 [15137275.001]
  • [Cites] Sex Transm Infect. 2004 Jun;80(3):236-40 [15170012.001]
  • [Cites] Sex Transm Infect. 2004 Aug;80(4):324 [15295136.001]
  • [Cites] Sex Transm Infect. 2004 Aug;80(4):326-7 [15295139.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1981 Jun 5;30(21):250-2 [6265753.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] Lancet. 1981 Dec 12;2(8259):1339 [6118728.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1982 Sep 24;31(37):507-8, 513-4 [6815471.001]
  • [Cites] Lancet. 1983 Apr 16;1(8329):872 [6132195.001]
  • [Cites] Lancet. 1984 Sep 1;2(8401):477-80 [6147546.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Oct 20;289(6451):1041 [6435762.001]
  • [Cites] Br Med J (Clin Res Ed). 1985 Apr 20;290(6476):1176-8 [2985170.001]
  • [Cites] Lancet. 1985 Jun 1;1(8440):1261-2 [2860454.001]
  • [Cites] Lancet. 1985 Sep 7;2(8454):541-2 [2863552.001]
  • [Cites] Lancet. 1986 Jan 18;1(8473):155 [2867370.001]
  • [Cites] Lancet. 1986 May 24;1(8491):1179-82 [2871421.001]
  • [Cites] Lancet. 1986 Oct 18;2(8512):920 [2876351.001]
  • [Cites] Lancet. 1987 Mar 21;1(8534):656-8 [2882084.001]
  • [Cites] Br Med J (Clin Res Ed). 1988 May 7;296(6632):1289-92 [3133053.001]
  • [Cites] BMJ. 1989 Feb 18;298(6671):419-22 [2495047.001]
  • [Cites] BMJ. 1989 Nov 25;299(6711):1295-8 [2513926.001]
  • [Cites] Int J STD AIDS. 1990 Jan;1(1):10-7 [2099193.001]
  • [Cites] BMJ. 1991 Jun 8;302(6789):1365-7 [2059714.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):671 [1347351.001]
  • [Cites] AIDS. 1992 May;6(5):495-500 [1616656.001]
  • [Cites] Commun Dis Rep CDR Wkly. 1993 Jan 22;3(4):13 [7694746.001]
  • [Cites] CDR (Lond Engl Rev). 1991 Apr 26;1(5):R51-6 [1669774.001]
  • [Cites] Sex Transm Dis. 2005 Apr;32(4):220-6 [15788919.001]
  • [Cites] Sex Transm Infect. 2005 Aug;81(4):345-50 [16061545.001]
  • [Cites] Int J STD AIDS. 2005 Sep;16(9):618-21 [16176629.001]
  • [Cites] Euro Surveill. 2004 Dec;9(12):21-5 [15677851.001]
  • [Cites] Sex Transm Infect. 2005 Oct;81(5):367-72 [16199733.001]
  • [Cites] AIDS. 2005 Dec 2;19(18):2171-4 [16284470.001]
  • [Cites] BMJ. 2005 Dec 10;331(7529):1368 [16299012.001]
  • [Cites] Sex Transm Infect. 2006 Jun;82 Suppl 3:iii78-86 [16735298.001]
  • [Cites] Sex Transm Infect. 2007 Apr;83(2):120-5; discussion 125 [17090569.001]
  • [Cites] Sex Transm Infect. 2007 Jun;83(3):185-8 [17229791.001]
  • [Cites] Sex Transm Dis. 2007 Oct;34(10):783-90 [17495592.001]
  • [Cites] Sex Transm Infect. 1999 Oct;75(5):332-6 [10616358.001]
  • [Cites] AIDS. 2000 May 5;14(7):853-61 [10839594.001]
  • [Cites] Lancet. 2000 Jul 22;356(9226):291-6 [11071184.001]
  • [Cites] BMJ. 2000 Nov 25;321(7272):1319-20 [11090514.001]
  • [Cites] Am J Epidemiol. 2001 May 1;153(9):898-902 [11323321.001]
  • [Cites] BMJ. 2001 May 5;322(7294):1087-8 [11337435.001]
  • [Cites] Sex Transm Infect. 2001 Aug;77(4):242-7 [11463922.001]
  • [Cites] J Infect. 2001 Feb;42(2):134-9 [11531320.001]
  • [Cites] Commun Dis Rep CDR Rev. 1997 May 30;7(6):R77-82 [9185380.001]
  • (PMID = 17662168.001).
  • [ISSN] 0950-2688
  • [Journal-full-title] Epidemiology and infection
  • [ISO-abbreviation] Epidemiol. Infect.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 94
  • [Other-IDs] NLM/ PMC2870809
  •  go-up   go-down


76. Kiertiburanakul S, Likhitpongwit S, Ratanasiri S, Sungkanuparph S: Malignancies in HIV-infected Thai patients. HIV Med; 2007 Jul;8(5):322-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies in HIV-infected Thai patients.
  • Of 1416 HIV-infected patients seen at Ramathibodi Hospital over a 5-year period (1999-2003), 42 were diagnosed with malignancies, giving a prevalence of 3%.
  • AIDS-related malignancies were found in 26 patients (62%).
  • The most common AIDS-related malignancies were non-Hodgkin's lymphoma (NHL) (33%), cervical cancer (21%) and Kaposi's sarcoma (KS) (5%).
  • Breast cancer was the most common non-AIDS-related malignancy (10%).
  • [MeSH-major] HIV. HIV Infections / complications. Neoplasms / virology


77. Mlombe Y: Management of HIV associated Kaposi's sarcoma in Malawi. Malawi Med J; 2008 Dec;20(4):129-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of HIV associated Kaposi's sarcoma in Malawi.
  • Kaposi's sarcoma is a common malignancy in Malawi and is often managed with single agent vincristine.
  • This article outlines feasible combination chemotherapy for Kaposi's sarcoma in Malawi which should be made more widely available.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma, Kaposi / drug therapy
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. HIV-1. Humans. Malawi


78. Phatak UA, Joshi R, Badakh DK, Gosavi VS, Phatak JU, Jagdale RV: AIDS-associated cancers: an emerging challenge. J Assoc Physicians India; 2010 Mar;58:159-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated cancers: an emerging challenge.
  • OBJECTIVES: To study the incidence and effects of anti-retroviral therapy along with cancer chemotherapy on outcome of AIDS associated Cancers in Indian patients.
  • 46 AIDS-associated cancers were identified.
  • HIV status was evaluated by ELISA, Western Blot, viral load and CD4/CD8 counts.
  • RESULTS: Incidence of AIDS-associated cancers was 1.2 percent.
  • AIDS-Defining Cancers (ADC) were seen in 26 (54.35%) while non-AIDS-Defining Cancers (NADC) were observed in 21 (45.65%).
  • Non Hodgkin Lymphoma was the commonest form of AIDS-defining cancers in 21 (84%) patients, cervical cancers in 4 (16%) women while there was not a single case of Kaposi's Sarcoma.
  • AIDS associated cancers were common in males.
  • Only 33.5% patients received treatment for HIV and cancers.
  • Development of immune reconstitution syndrome was observed in 9.09% patients.
  • CONCLUSIONS: AIDS-associated cancers are seen in advanced stage of HIV infection.
  • Cervical cancers and non-AIDS-defining cancers do not show predictable response to anti-retroviral therapy.
  • Mortality in non-AIDS related cancers was significantly higher than AIDS related cancers.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Neoplasms / drug therapy


79. Ayers LW, Silver S, McGrath MS, Orenstein JM: The AIDS and Cancer Specimen Resource: role in HIV/AIDS scientific discovery. Infect Agent Cancer; 2007;2:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The AIDS and Cancer Specimen Resource: role in HIV/AIDS scientific discovery.
  • The AIDS Cancer and Specimen Resource (ACSR) supports scientific discovery in the area of HIV/AIDS-associated malignancies.
  • The ACSR was established as a cooperative agreement between the NCI (Office of the Director, Division of Cancer Treatment and Diagnosis) and regional consortia, University of California, San Francisco (West Coast), George Washington University (East Coast) and Ohio State University (Mid-Region) to collect, preserve and disperse HIV-related tissues and biologic fluids and controls along with clinical data to qualified investigators.
  • The ACSR tissue bank has more than 100,000 human HIV positive specimens that represent different processing (43), specimen (15), and anatomical site (50) types.
  • Requests have been greatest for Kaposi's sarcoma (32%) and non-Hodgkin's lymphoma (26%).
  • ACSR also provides tissue microarrays of, e.g., Kaposi's sarcoma and non-Hodgkin's lymphoma, for biomarker assays and has developed collaborations with other groups that provide access to additional AIDS-related malignancy specimens.
  • The ACSR promotes the scientific exploration of the relationship between HIV/AIDS and malignancy by participation at national and international scientific meetings, contact with investigators who have productive research in this area and identifying, collecting, preserving, enhancing, and dispersing HIV/AIDS-related malignancy specimens to funded, approved researchers at no fee.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Res. 2003 Oct 15;60(1):108-18 [14522412.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2004;50 Online Pub:OL581-9 [15555424.001]
  • [Cites] Pediatr Infect Dis J. 2005 Mar;24(3):237-42 [15750460.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] BMC Med Inform Decis Mak. 2005;5:12 [15871741.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1373-80 [15923317.001]
  • [Cites] Science. 2005 Jun 10;308(5728):1582-3 [15947174.001]
  • [Cites] BMC Med Inform Decis Mak. 2005;5:25 [16086837.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Int J Hematol. 2006 Jul;84(1):3-11 [16867895.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):696-701 [10655369.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Nat Med. 2001 Jan;7(1):73-9 [11135619.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):733-41 [12428794.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] BMC Med Inform Decis Mak. 2003 May 23;3:5 [12769826.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4620-9 [8977254.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Jan 20;13(2):135-49 [9007199.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • (PMID = 17335575.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA066531
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1851770
  •  go-up   go-down


80. Palmieri C, Treibel T, Large O, Bower M: AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy. QJM; 2006 Dec;99(12):811-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy.
  • Highly active antiretroviral therapy (HAART) has had a dramatic effect on the natural history of HIV disease, reducing the incidence of opportunistic infections and Kaposi's sarcoma, and improving overall survival.
  • Since HAART became available in 1996, the incidence of AIDS-related non-Hodgkin's lymphoma (NHL) has fallen, and although there has been no change in the clinical features at presentation, the overall survival of patients with AIDS-related NHL has improved.
  • Prognosis is now determined chiefly by lymphoma-associated factors similar to those in the general population (the International Prognostic Index), although serum CD4 count at lymphoma diagnosis is an additional independent prognostic factor.
  • The management of patients with AIDS-related NHL with either infusional chemotherapy or CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine and prednisolone) achieves response and survival rates approaching those observed in the general population.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Neutropenia / therapy. Sarcoma, Kaposi / drug therapy


81. Sekiya N, Imamura A: [Doxil--pegylated liposomal doxorubicin]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1439-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pegylated liposomal doxorubicin (Doxil: PLD) is a liposome-encapsulated form of doxorubicin modified with polyethylene glycol that has been approved for the treatment of AIDS-related Kaposi's sarcoma.
  • This does not mean, however, that PLD should be used in the treatment of all patients with Kaposi's sarcoma; in some cases with skin lesions only and local distribution highly active antiretroviral therapy (HAART) alone is effective.
  • [MeSH-minor] Adult. Clinical Trials as Topic. Female. Humans. Male. Middle Aged. Sarcoma, Kaposi / drug therapy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701868.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


82. Kreuter A, Rasokat H, Klouche M, Esser S, Bader A, Gambichler T, Altmeyer P, Brockmeyer NH: Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Invest; 2005;23(8):653-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.
  • BACKGROUND: Classic Kaposi's sarcoma (KS) is a rare neoplasm, predominantly occurring in older subjects of Eastern Europe or Mediterranean descent.
  • While single lesions may be treated by simple excision, laser therapy, cryotherapy, or intralesional therapy, advanced or disseminated disease requires systemic treatment.
  • Several studies reported the effectiveness of pegylated liposomal doxorubicin (PLD) and low-dose recombinant interferon alfa-2a (IFNalpha) in the treatment of AIDS-associated KS.
  • OBJECTIVE: The aim of this retrospective analysis of three German centers was to compare the effectiveness and tolerability of PLD with IFNalpha in patients with advanced classic KS.
  • METHODS: Retrospective analysis of 18 Caucasian patients who had been treated for histologically proven classic KS, with either with PLD or IFNalpha was performed.
  • RESULTS: In the 12 KS patients treated with PLD, complete response (CR) was achieved in 8 (67 percent), major response (MR) in 3 (25 percent), and minor response (mR) in 1 (8 percent).
  • Stable disease (SD) or progression of disease (PD) was not observed.
  • Neutropenia (33 percent) related to PLD was the most common adverse event (4/12).
  • Flu-like symptoms in 3 patients (50 percent) related to IFNalpha were the most common adverse events.
  • CONCLUSION: This retrospective analysis of patients with classic KS confirms the efficacy and safety of PLD.
  • PLD is superior to IFNalpha and should be considered as an promising option in the treatment of advanced classic KS.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / analogs & derivatives. Interferon-alpha / administration & dosage. Interferon-alpha / therapeutic use. Polyethylene Glycols / therapeutic use. Sarcoma, Kaposi / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Germany. Humans. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377582.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 76543-88-9 / interferon alfa-2a; 80168379AG / Doxorubicin
  •  go-up   go-down


83. Meibodi NT, Nahidi Y, Mahmoudi M, Javidi Z, Rastin M, Sheikh A, Esmaeeli HA: Evaluation of coexistence of the Human Herpesvirus type 8 (HHV-8) infection and pemphigus. Int J Dermatol; 2010 Jul;49(7):780-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of coexistence of the Human Herpesvirus type 8 (HHV-8) infection and pemphigus.
  • BACKGROUND: Human Herpesvirus type 8 (HHV-8) is a new member of the herpes virus family, first found in the tissue of acquired immune deficiency syndrome (AIDS)-related Kaposi's sarcoma.

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20618497.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


84. Lechowicz M, Dittmer DP, Lee JY, Krown SE, Wachsman W, Aboulafia D, Dezube BJ, Ratner L, Said J, Ambinder RF: Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid. Clin Infect Dis; 2009 Dec 15;49(12):1946-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid.
  • The AIDS Malignancy Consortium undertook a pilot trial of valproic acid among patients with AIDS-associated Kaposi sarcoma (KS).
  • Treatment was associated with low toxicity, but the KS clinical response and KS herpesvirus lytic induction rates were not sufficiently high to meet predefined criteria for efficacy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Sarcoma, Kaposi / drug therapy. Valproic Acid / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2000 May 5;14(7):899-902 [10839602.001]
  • [Cites] AIDS. 2001 Jul 27;15(11):1449-50 [11504972.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):153-9 [11773164.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]
  • [Cites] CNS Drug Rev. 2003 Summer;9(2):199-216 [12847559.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] Lancet. 2005 Aug 13-19;366(9485):549-55 [16099290.001]
  • [Cites] J Infect Dis. 2007 Mar 15;195(6):833-6 [17299713.001]
  • [Cites] N Engl J Med. 2007 Sep 27;357(13):1352-3 [17898112.001]
  • [Cites] N Engl J Med. 2008 Jan 31;358(5):535-6; author reply 536 [18234764.001]
  • [Cites] Nat Med. 2008 Oct;14(10):1118-22 [18776891.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2496-502 [19349542.001]
  • (PMID = 19911999.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01CA070062; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA163217; United States / NCI NIH HHS / CA / U01 CA070047; United States / NCI NIH HHS / CA / U01 CA070019-08; United States / NCI NIH HHS / CA / U01 CA070019; United States / NIDCR NIH HHS / DE / DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NCI NIH HHS / CA / U01 CA083035; United States / NCI NIH HHS / CA / P01 CA081400-04; United States / NCI NIH HHS / CA / P01 CA113239; United States / NCI NIH HHS / CA / U01 CA066535; United States / NCI NIH HHS / CA / U01 CA083118; United States / NCI NIH HHS / CA / U01CA121947; United States / NCI NIH HHS / CA / U01 CA071375; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / U01CA083118; United States / NCI NIH HHS / CA / U01CA071375; United States / NCI NIH HHS / CA / U01CA70054; United States / NCI NIH HHS / CA / U01CA070047; United States / NCI NIH HHS / CA / U01 CA070054; United States / NCI NIH HHS / CA / P01 CA081400; United States / NCI NIH HHS / CA / U01CA070019; United States / NCI NIH HHS / CA / P01CA113239; United States / NCI NIH HHS / CA / UO1CA66535; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / U01 CA121947-016805; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / U01 CA070019-09; United States / NCI NIH HHS / CA / U01 CA070062; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / U01CA083035; United States / NCI NIH HHS / CA / U01 CA121947
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral; 614OI1Z5WI / Valproic Acid
  • [Other-IDs] NLM/ NIHMS146832; NLM/ PMC2952388
  •  go-up   go-down


85. Qin Z, Kearney P, Plaisance K, Parsons CH: Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. J Leukoc Biol; 2010 Jan;87(1):25-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes.
  • Macrophages are an important source of inflammatory cytokines generated during the innate immune response,but in the microenvironment of certain tumors,macrophages promote tumor progression through their preferential secretion of cytokines that support tumor cell growth and suppress antitumoral immune responses.
  • KSHV is the causative agent of KS and lymphomas preferentially arising in immuno compromised patients, and specific cytokines, including IL-6 and IL-10, have been implicated in KSHV-associated cancer pathogenesis.
  • However, the contribution of KSHV-infected macrophages to the cytokine milieu within KSHV-related tumors is unclear.
  • In addition,RNA interference specifically targeting LIP induced basal secretion of IL-6 and IL-10 by macrophages.Taken together, these data support a role for KSHV miRNA in the programming of macrophage cytokine responses in favor of KSHV-related tumor progression.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1998 Feb 1;91(3):968-76 [9446658.001]
  • [Cites] Annu Rev Immunol. 2001;19:683-765 [11244051.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2069-73 [10979949.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Leukemia. 1999 Apr;13(4):634-40 [10214873.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] J Invest Dermatol. 2004 Dec;123(6):1169-75 [15610530.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5 [15800047.001]
  • [Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]
  • [Cites] Clin Exp Allergy. 2005 Jun;35(6):782-9 [15969670.001]
  • [Cites] AIDS. 2005 Jul 22;19(11):1229-31 [15990578.001]
  • [Cites] J Virol. 2005 Jul;79(14):9301-5 [15994824.001]
  • [Cites] Mol Cell. 2005 Oct 7;20(1):3-7 [16209940.001]
  • [Cites] AIDS. 2005 Nov 4;19(16):1907-10 [16227799.001]
  • [Cites] J Immunol. 2001 Apr 1;166(7):4312-8 [11254683.001]
  • [Cites] J Virol. 2002 May;76(10):4688-98 [11967286.001]
  • [Cites] Biochem J. 2002 Aug 1;365(Pt 3):561-75 [12006103.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10683-8 [12145325.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]
  • [Cites] Cytokine. 2003 Mar 7;21(5):242-7 [12824009.001]
  • [Cites] J Immunol. 2003 Jul 15;171(2):821-8 [12847250.001]
  • [Cites] J Virol. 2003 Aug;77(16):8893-914 [12885907.001]
  • [Cites] J Biomed Sci. 2004 Jul-Aug;11(4):517-27 [15153787.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Science. 1989 Nov 17;246(4932):911-6 [2683088.001]
  • [Cites] Cell. 1991 Nov 1;67(3):569-79 [1934061.001]
  • [Cites] Adv Immunol. 1994;56:1-26 [8073945.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] J Virol. 1997 Oct;71(10):7963-8 [9311888.001]
  • [Cites] Ann Diagn Pathol. 1999 Dec;3(6):357-63 [10594287.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10794-800 [16322225.001]
  • [Cites] Nat Immunol. 2006 Feb;7(2):131-7 [16424890.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1963-73 [16794734.001]
  • [Cites] Cell Signal. 2006 Nov;18(11):1865-75 [16600570.001]
  • [Cites] J Virol. 2006 Nov;80(21):10874-8 [16956953.001]
  • [Cites] J Virol. 2006 Dec;80(24):12171-86 [17020951.001]
  • [Cites] J Leukoc Biol. 2007 Jan;81(1):221-8 [17023556.001]
  • [Cites] J Interferon Cytokine Res. 2006 Dec;26(12):893-900 [17238832.001]
  • [Cites] J Infect Dis. 2007 Mar 1;195(5):645-59 [17262705.001]
  • [Cites] J Biochem. 2007 Feb;141(2):137-45 [17190786.001]
  • [Cites] J Virol. 2007 May;81(10):5079-90 [17329329.001]
  • [Cites] PLoS Pathog. 2007 May 11;3(5):e65 [17500590.001]
  • [Cites] Immunol Cell Biol. 2007 Aug-Sep;85(6):420-4 [17637696.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2685-95 [17525287.001]
  • [Cites] Eur J Immunol. 2007 Oct;37(10):2900-11 [17899538.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):272-86 [18328430.001]
  • [Cites] J Biol Chem. 2008 Mar 14;283(11):6843-53 [18195020.001]
  • [Cites] J Immunol. 2008 Apr 15;180(8):5689-98 [18390754.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Virol. 2008 Jun;82(11):5440-9 [18367536.001]
  • [Cites] Immunol Lett. 2008 Oct 30;120(1-2):37-41 [18680763.001]
  • [Cites] Cytokine. 2008 Sep;43(3):391-4 [18701320.001]
  • [Cites] Cell Host Microbe. 2008 Nov 13;4(5):470-83 [18996347.001]
  • [Cites] J Immunol. 2009 Feb 15;182(4):2258-68 [19201880.001]
  • [Cites] J Cell Physiol. 2009 Jun;219(3):698-706 [19229882.001]
  • [CommentIn] J Leukoc Biol. 2010 Jan;87(1):9-12 [20047884.001]
  • (PMID = 20052801.001).
  • [ISSN] 1938-3673
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA142362; United States / NCRR NIH HHS / RR / P20-RR-017696; United States / NCI NIH HHS / CA / K08 CA103858-05; United States / NCI NIH HHS / CA / CA103858-05; United States / NCRR NIH HHS / RR / P20 RR017696-085957; United States / NCI NIH HHS / CA / P30 CA138313; United States / NCI NIH HHS / CA / K08-1CA103858; United States / NCRR NIH HHS / RR / RR017696-085957; United States / NCI NIH HHS / CA / K08 CA103858; United States / NCRR NIH HHS / RR / P20 RR017696; United States / NCI NIH HHS / CA / P30-CA-138313
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / CCAAT-Enhancer-Binding Protein-beta; 0 / IL10 protein, human; 0 / IL6 protein, human; 0 / Interleukin-6; 0 / MicroRNAs; 0 / Protein Isoforms; 0 / RNA, Viral; 130068-27-8 / Interleukin-10
  • [Other-IDs] NLM/ PMC2801620
  •  go-up   go-down


86. Mohanna S, Maco V, Bravo F, Gotuzzo E: Epidemiology and clinical characteristics of classic Kaposi's sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: a critical review of an old disease. Int J Infect Dis; 2005 Sep;9(5):239-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and clinical characteristics of classic Kaposi's sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: a critical review of an old disease.
  • OBJECTIVE: To review the current South American literature on classic Kaposi's sarcoma (KS) and human herpesvirus 8 (HHV-8), and point the way for studies that still need to be performed.
  • MATERIALS AND METHODS: The authors performed an exhaustive search in LILACS, SCIELO and PUBMED databases for classic KS and HHV-8 in South America.
  • The classic KS form seen in Colombia resembles the type of disease seen among African communities; the same unusual presentation with confluent exophytic nodules or eroded lesions has been noticed in Peru.
  • Five specimens from Argentina were subtyped: (three classic KS and two AIDS KS); the identified strains fell into subtypes A and C.
  • AIDS-related KS specimens from Brazil and Venezuela were subtyped: (43 and nine respectively); analysis grouped them predominantly into subgroups A, B and C.
  • In French Guiana ten endemic KS and six AIDS-related KS specimens were subtyped; analysis grouped them predominantly into subgroups A, B and C.
  • CONCLUSION: Classic KS in South America has a very similar clinical presentation but not the same as the classic KS variety described in the Mediterranean.
  • Finally, the key to understanding the precise molecular epidemiology and phylogenetic distribution of HHV-8 in South America would be to perform more subtyping of classic KS cases.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Antibodies, Viral / blood. Gastrointestinal Neoplasms / epidemiology. Hematologic Neoplasms / epidemiology. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / classification. Herpesvirus 8, Human / immunology. Lung Neoplasms / epidemiology. Sarcoma, Kaposi / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16095940.001).
  • [ISSN] 1201-9712
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antibodies, Viral
  • [Number-of-references] 60
  •  go-up   go-down


87. Akanmu AS: AIDS-associated malignancies. Afr J Med Med Sci; 2006 Dec;35 Suppl:57-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated malignancies.
  • A number of immunodeficiency states--both inherited (such as agammaglobulinaemia, Bloom's syndrome, hereditary telangiectasia) and acquired (e.g. immunosuppressive therapy) have been associated with varieties of cancers.
  • HIV induces more profound immunodeficiency state and it should not be difficult to imaging why cancer diagnosis is made in over 40% of HIV infected patients.
  • Impairment of normal function of natural killer cells as a result of lack of helper signals from CD4+ T-lymphocytes may be a major mechanism of increased susceptibility to cancer development in HIV infected patients.
  • Three neoplastic diseases are associated so commonly with HIV infection that each of them has become recognized as an AIDS defining illness.
  • These are Kaposi's Sarcoma (KS), Non-Hodgkin's Lymphoma (NHL) and Cervical Carcinoma.
  • Both KS and NHL were recognized as AIDS associated cancers from the onset of the epidemic in 1981 but carcinoma of the cervix became AIDS defining in 1993.
  • The epidemiology, aetiopathogenesis, clinical manifestation, diagnostic tools and modalities of therapeutic intervention for KS and NHL form the subject of this review.
  • [MeSH-major] HIV. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Sarcoma, Kaposi / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050776.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Nigeria
  • [Number-of-references] 114
  •  go-up   go-down


88. Mohanna S, Maco V, Gown A, Morales D, Bravo F, Gotuzzo E: Is classic Kaposi's sarcoma endemic in Peru?: report of a case in an indigenous patient. Am J Trop Med Hyg; 2006 Aug;75(2):324-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is classic Kaposi's sarcoma endemic in Peru?: report of a case in an indigenous patient.
  • Kaposi's sarcoma (KS) has been classified in four clinical variants (classic or Mediterranean; endemic or African; epidemic or AIDS-related; iatrogenic or immunosuppression-related).
  • ELISA-HIV tests were negative and immunohistochemistry (IHC) of the tumor tissue was positive for HHV-8.
  • We also review all available Peruvian literature of classic KS, a disease that has been frequently reported in indigenous population of Peru since 1968, making this country a possible endemic zone of classic KS.
  • [MeSH-major] Endemic Diseases. Herpesvirus 8, Human / isolation & purification. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / virology

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896142.001).
  • [ISSN] 0002-9637
  • [Journal-full-title] The American journal of tropical medicine and hygiene
  • [ISO-abbreviation] Am. J. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


89. Murray JF: Pulmonary complications of HIV-1 infection among adults living in Sub-Saharan Africa. Int J Tuberc Lung Dis; 2005 Aug;9(8):826-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary complications of HIV-1 infection among adults living in Sub-Saharan Africa.
  • Sub-Saharan Africa, which has just over 10% of the world's population, is home to more than 25 million people living with HIV/AIDS-two thirds of the global total.
  • Opportunistic pulmonary infections are major causes of morbidity and mortality among HIV-infected adults in the subcontinent.
  • Of these diseases, tuberculosis (TB) is by far the most prevalent and serious, and in some countries it causes one third or more of all AIDS-related deaths.
  • Because it is so frequent and a major public health problem, TB tops the list of differential diagnoses of people-with or without coexisting HIV infection-who present to the health care system with chronic cough and other pulmonary symptoms.
  • As HIV-induced immunosuppression worsens, the clinical and radiographic manifestations of TB become increasingly atypical.
  • Second among HIV/AIDS-associated pulmonary complications is community-acquired pneumonia, most commonly caused by Streptococcus pneumoniae, which usually responds to standard beta-lactam antimicrobial agents.
  • Pulmonary nocardiosis, cryptococcosis, Kaposi's sarcoma, and (possibly) histoplasmosis appear to be infrequent, but probably underdiagnosed.
  • Improved diagnosis, treatment, and prevention of all these diseases are urgently needed, but a greatly expanded antiretroviral treatment program will help most of all.
  • [MeSH-major] HIV Infections / complications. HIV-1 / pathogenicity. Public Health. Tuberculosis, Pulmonary / epidemiology. Tuberculosis, Pulmonary / etiology
  • [MeSH-minor] Africa / epidemiology. Community-Acquired Infections. Humans. Immunocompromised Host. Opportunistic Infections / epidemiology. Opportunistic Infections / pathology. Pneumocystis jirovecii. Pneumonia, Pneumocystis / epidemiology. Pneumonia, Pneumocystis / etiology. Pneumonia, Pneumocystis / pathology. Prevalence


90. Whitman AG, Bryan BA, Dyson OF, Patel DK, Ramasamy D, Anantharaman S, Reber AJ, Akula SM: AIDS related viruses, their association with leukemia, and Raf signaling. Curr HIV Res; 2005 Oct;3(4):319-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS related viruses, their association with leukemia, and Raf signaling.
  • Over time, this expanding population of poorly/non- functional white blood cells overwhelms the normal function of the body's blood and immune systems.
  • In this review, we present an update on the role of AIDS related viruses as an etiology for leukemia.
  • Human immunodeficiency virus-1 and -2 (HIV-1; -2) are the cause for the development of acquired immune deficiency syndrome (AIDS).
  • Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), Human papillomavirus (HPV), and Kaposi's sarcoma-associated herpesvirus (KSHV) are specifically implicated in AIDS associated malignancies.
  • However, there are other viruses that are associated to a lesser extent with the AIDS condition and they are Human T-cell leukemia virus-1 (HTLV-1), hepatitis B virus (HBV), hepatitis C virus (HCV), and human herpesvirus-6 (HHV-6).
  • Of these viruses, HTLV-1 has been etiologically associated with leukemia.
  • Raf signaling has been shown to aid in the infection and pathogenesis of many of these viruses, making Raf pathway components good potential targets for the treatment of leukemia induced by AIDS related viruses.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / virology. Leukemia / virology. raf Kinases / metabolism


91. Attia S, Dezube BJ, Torrealba JR, Sosman JM, McHaffie DR, Pfau PR, Bailey HH, Kozak KR: AIDS-related Kaposi's sarcoma of the gastrointestinal tract. J Clin Oncol; 2010 Jun 01;28(16):e250-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Kaposi's sarcoma of the gastrointestinal tract.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / methods. Biopsy, Needle. Doxorubicin / therapeutic use. Drug Therapy, Combination. Follow-Up Studies. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / etiology. Gastrointestinal Neoplasms / pathology. HIV Infections / complications. HIV Infections / diagnosis. HIV Infections / drug therapy. Humans. Immunohistochemistry. Male. Neoplasm Staging. Risk Assessment. Severity of Illness Index. Treatment Outcome


92. Cheung MC, Pantanowitz L, Dezube BJ: AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist; 2005 Jun-Jul;10(6):412-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
  • Human immunodeficiency virus (HIV)-infected patients are at increased risk of developing cancer, particularly in the later stages of acquired immune deficiency syndrome (AIDS).
  • Kaposi's sarcoma (KS) and AIDS-related non-Hodgkin's lymphoma (ARL) are the most common AIDS-defining malignancies.
  • AIDS-related KS varies from minimal to fulminant disease.
  • Treatment decisions for AIDS-related KS are guided largely by the presence and extent of symptomatic disease.
  • In addition to HAART, excellent treatments exist for both localized disease (topical gel, radiotherapy, and intralesional therapy) and advanced disease (liposomal anthracyclines, paclitaxel).
  • Novel therapies that have become available to treat AIDS-related KS include angiogenesis inhibitors and antiviral agents.
  • With the immune restoration afforded by HAART, standard-dose chemotherapies now can be safely administered to treat ARL with curative intent.
  • The role of analogous treatments used in HIV-negative patients, including monoclonal antibodies and autologous stem cell transplantation, requires further clarification in HIV-positive patients.
  • HIV-infected patients also appear to be at increased risk for developing certain non-AIDS-defining cancers, such as Hodgkin's lymphoma and multiple myeloma.
  • Although the optimal treatment of these neoplasms is at present uncertain, recent advances in chemotherapy, antiretroviral drugs, and supportive care protocols are allowing for more aggressive management of many of the AIDS-related cancers.
  • This article provides an up-to-date review of the epidemiology, pathogenesis, clinical features, and treatment of various AIDS-related malignancies that are likely to be encountered by an oncologist practicing in the current HAART era.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Medical Oncology / trends. Sarcoma, Kaposi / drug therapy


93. Zong JC, Arav-Boger R, Alcendor DJ, Hayward GS: Reflections on the interpretation of heterogeneity and strain differences based on very limited PCR sequence data from Kaposi's sarcoma-associated herpesvirus genomes. J Clin Virol; 2007 Sep;40(1):1-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reflections on the interpretation of heterogeneity and strain differences based on very limited PCR sequence data from Kaposi's sarcoma-associated herpesvirus genomes.
  • Ever since the original identification of fragments of KSHV DNA in Kaposi's sarcoma (KS) tissue by Chang et al. in 1994, PCR has been used successfully and extensively to detect the virus in clinical samples from the accepted etiological diseases of KS, PEL and MCD.
  • However, a number of other clinical and epidemiological studies claiming evidence for KSHV in multiple myeloma or sarcoid and more recently in primary pulmonary hypertension, as well as claims about the biological significance of DNA sequence polymorphisms based just on small ORF26 PCR DNA fragments have not been convincing.
  • Here, we evaluate the validity and interpretations of previous results in the context of both the observed rates and global patterns of sequence variability within an extended ORF26 locus, as well as from the perspective of the overall levels of KSHV variability found after sampling multiple loci across the complete KSHV genome.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1997 Jul 15;11(9):1119-22 [9233458.001]
  • [Cites] J Infect Dis. 1997 Jul;176(1):94-102 [9207354.001]
  • [Cites] Br J Dermatol. 1997 Aug;137(2):179-84 [9292063.001]
  • [Cites] J Med Virol. 1997 Sep;53(1):81-4 [9298737.001]
  • [Cites] J Virol. 1997 Oct;71(10):8082-3 [9311909.001]
  • [Cites] Arch Dermatol. 1997 Oct;133(10):1247-51 [9382563.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4278-82 [9373238.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1655-61 [9400509.001]
  • [Cites] Science. 1997 Dec 12;278(5345):1972; author reply 1972-3 [9417645.001]
  • [Cites] J Infect Dis. 1998 Jan;177(1):213-6 [9419191.001]
  • [Cites] Am J Epidemiol. 1998 Feb 1;147(3):217-21 [9482495.001]
  • [Cites] Lancet. 1998 Feb 28;351(9103):679-80 [9500364.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1500-8 [9525993.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4393-4 [9596693.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2681-7 [9763550.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1091-6 [9781647.001]
  • [Cites] J Infect Dis. 1998 Nov;178(5):1546-7 [9780286.001]
  • [Cites] J Infect Dis. 1998 Dec;178(6):1610-5 [9815212.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1110-1 [10025982.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1482-6 [10029574.001]
  • [Cites] J Virol. 1999 May;73(5):4156-70 [10196312.001]
  • [Cites] Blood. 1999 May 15;93(10):3157-9; discussion 3164-6 [10233867.001]
  • [Cites] Blood. 1999 May 15;93(10):3159-63; discussion 3163-4 [10233868.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):187-99 [10343070.001]
  • [Cites] J Virol. 1999 Aug;73(8):6646-60 [10400762.001]
  • [Cites] J Leukoc Biol. 1999 Aug;66(2):357-60 [10449181.001]
  • [Cites] J Infect Dis. 1999 Nov;180(5):1466-76 [10515805.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Dec 15;172(12):1581-5 [16192453.001]
  • [Cites] Intervirology. 2006;49(3):133-43 [16428889.001]
  • [Cites] Adv Dent Res. 2006;19(1):91-5 [16672557.001]
  • [Cites] J Clin Microbiol. 2006 Jul;44(7):2409-15 [16825357.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:1-42 [17089792.001]
  • [Cites] J Clin Virol. 2007 Sep;40(1):19-25 [17690010.001]
  • [Cites] Rev Med Virol. 2002 Jan-Feb;12(1):47-63 [11787083.001]
  • [Cites] Br J Haematol. 2000 Jan;108(1):197-8 [10712004.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1785-90 [10823785.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):151-2 [11001045.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4226-33 [11106236.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):32-8 [11227070.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1409-13 [11301386.001]
  • [Cites] J Clin Virol. 2002 Jan;23(3):119-48 [11595592.001]
  • [Cites] J Gen Virol. 2002 Jul;83(Pt 7):1613-9 [12075079.001]
  • [Cites] J Virol. 2003 Jun;77(11):6546-50 [12743312.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2492-7 [12791871.001]
  • [Cites] J Infect Dis. 2003 Sep 1;188(5):678-89 [12934184.001]
  • [Cites] N Engl J Med. 2003 Sep 18;349(12):1113-22 [13679525.001]
  • [Cites] J Virol. 2004 Apr;78(8):4074-84 [15047824.001]
  • [Cites] Oral Microbiol Immunol. 2004 Jun;19(3):201-4 [15107073.001]
  • [Cites] Biotechniques. 1994 Feb;16(2):242-4, 246 [8179886.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):759-61 [7891487.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] N Engl J Med. 1996 May 2;334(18):1168-72 [8602183.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4937-43 [8652805.001]
  • [Cites] J Clin Microbiol. 1996 Oct;34(10):2635-8 [8880542.001]
  • [Cites] J Infect Dis. 1997 Mar;175(3):703-7 [9041349.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1686-9 [9057651.001]
  • [Cites] J Virol. 1997 May;71(5):4138-44 [9094697.001]
  • [Cites] Science. 1997 Jun 20;276(5320):1851-4 [9188529.001]
  • [Cites] J Neurol. 1997 Jul;244(7):450-4 [9266465.001]
  • (PMID = 17698410.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA081400-040001; United States / NCI NIH HHS / CA / R01 CA081422; United States / NIAID NIH HHS / AI / AI24576; United States / NCI NIH HHS / CA / P01 CA113239; United States / NCI NIH HHS / CA / R01 CA081422-05; United States / NCI NIH HHS / CA / CA73585; United States / NCI NIH HHS / CA / R01 CA073585-10; United States / NCI NIH HHS / CA / P01 CA081400; United States / NIAID NIH HHS / AI / R01 AI024576; United States / NCI NIH HHS / CA / CA081422-05; United States / NCI NIH HHS / CA / CA81422; United States / NCI NIH HHS / CA / CA073585-10; United States / NIAID NIH HHS / AI / R01 AI024576-20; United States / NCI NIH HHS / CA / CA081400-049001; United States / NCI NIH HHS / CA / R01 CA073585; United States / NIAID NIH HHS / AI / AI024576-20; United States / NCI NIH HHS / CA / P01 CA081400-040001; United States / NCI NIH HHS / CA / CA81400; United States / NCI NIH HHS / CA / P01 CA081400-049001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 61
  • [Other-IDs] NLM/ NIHMS30402; NLM/ PMC2084348
  •  go-up   go-down


94. Ranganathan K, Hemalatha R: Oral lesions in HIV infection in developing countries: an overview. Adv Dent Res; 2006 Apr 01;19(1):63-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral lesions in HIV infection in developing countries: an overview.
  • HIV infection is a major global health problem affecting developing and developed countries alike.
  • Oral lesions that are associated with this disease are important, since they affect the quality of life of the patient and are useful markers of disease progression and immunosuppression.
  • Oral lesions in HIV infection have been well-documented in developed countries, but there are fewer reports on oral lesions from developing countries.
  • Kaposi's sarcoma has been reported only from Africa and Latin America, while histoplasmosis and penicilliosis were reported in patients with advanced disease from Thailand.
  • HIV-associated salivary gland disease has a high prevalence in Africa and Latin America, especially in the pediatric group.
  • It is clear that there are considerable regional variations in the oral manifestations of HIV infection, depending both on the populations studied and on the clinical expertise available, among other factors.
  • Well-designed and -documented studies are necessary for the correct assessment of the nature and magnitude of the problem in developing countries, if oral health measures are to be effectively formulated for the HIV-infected.
  • [MeSH-major] Developing Countries. HIV Infections / complications. Mouth Diseases / complications. Mouth Diseases / epidemiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / epidemiology. Adult. Africa / epidemiology. Candidiasis, Oral / complications. Candidiasis, Oral / epidemiology. Child. Female. Gingivitis, Necrotizing Ulcerative / complications. Gingivitis, Necrotizing Ulcerative / epidemiology. Humans. India / epidemiology. Leukoplakia, Hairy / complications. Leukoplakia, Hairy / epidemiology. Male. Mexico / epidemiology. Mouth Neoplasms / complications. Mouth Neoplasms / epidemiology. Prevalence. Salivary Gland Diseases / complications. Salivary Gland Diseases / epidemiology. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / epidemiology. South America / epidemiology. Thailand / epidemiology


95. Lavolé A, Wislez M, Antoine M, Mayaud C, Milleron B, Cadranel J: Lung cancer, a new challenge in the HIV-infected population. Lung Cancer; 2006 Jan;51(1):1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer, a new challenge in the HIV-infected population.
  • HIV infection predisposes patients to AIDS-defining malignancies, some of which, such as Kaposi's sarcoma and non-Hodgkin lymphoma, can affect the lungs.
  • In 1996, AIDS-related mortality started to fall sharply in industrialized countries following the introduction of highly active antiretroviral treatments (HAART).
  • This was accompanied by an increase in the proportion of deaths attributable to non AIDS-defining solid tumors, and especially lung cancer (LC).
  • The increased risk of LC relative to the general population of the same age seems to be due partly to a higher prevalence of smoking among HIV-infected subjects.
  • The average age of HIV-infected patients at LC diagnosis is about 45 years.
  • Most patients are symptomatic at diagnosis and have only mild or moderate immunosuppression.
  • LC is diagnosed when it is locally advanced or metastatic (stages III-IV) in 75-90% of cases, as in patients with unknown HIV serostatus.
  • Adenocarcinoma is the most frequent histologic type.
  • The prognosis of LC is poorer in HIV-infected patients than in the general population.
  • Surgery remains the reference treatment for localized disease in patients with adequate functional status and general health, regardless of their immune status.
  • Prospective clinical trials are needed to define the optimal LC treatment strategies in HIV-infected patients.
  • [MeSH-major] HIV Infections / complications. Lung Neoplasms / etiology
  • [MeSH-minor] Global Health. HIV. Humans. Incidence. Risk Factors. Survival Rate


96. Yarchoan R, Pluda JM, Wyvill KM, Aleman K, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Little RF: Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity. Crit Rev Immunol; 2007;27(5):401-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity.
  • In this article, we review the preliminary evidence for the activity of interleukin-12 (IL-12) against Kaposi's sarcoma (KS) and discuss these results in the context of the biology of IL-12 and KS.
  • IL-12 is a cytokine that enhances type 1 immunity, induces production of interferon gamma (IFN-gamma), and mediates antiangiogenic effects.
  • In addition, it can downregulate a constitutively active G protein coupled receptor that is encoded by Kaposi's sarcoma-associated herpesvirus, the causative agent of KS.
  • These factors suggested that IL-12 might be worth exploring as a potential anti-KS agent.
  • In an initial phase I pilot study, IL-12 was found to have anti-KS activity when used alone in patients with AIDS-associated KS who were on a stable regimen of antiretroviral therapy.
  • In preliminary results from a subsequent study of the combination of IL-12 plus liposomal doxorubicin along with highly active antiretroviral therapy, remissions were obtained in a substantial percentage of patients with advanced AIDS-associated KS.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. HIV Infections / drug therapy. Interleukin-12 / therapeutic use. Sarcoma, Kaposi / drug therapy
  • [MeSH-minor] Anti-HIV Agents / administration & dosage. Anti-HIV Agents / therapeutic use. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antiretroviral Therapy, Highly Active. Clinical Trials as Topic. Cytokines / immunology. Cytokines / metabolism. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. HIV-1. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / physiology. Humans


97. Duprez R, Kassa-Kelembho E, Plancoulaine S, Brière J, Fossi M, Kobangue L, Minsart P, Huerre M, Gessain A: Human herpesvirus 8 serological markers and viral load in patients with AIDS-associated Kaposi's sarcoma in Central African Republic. J Clin Microbiol; 2005 Sep;43(9):4840-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human herpesvirus 8 serological markers and viral load in patients with AIDS-associated Kaposi's sarcoma in Central African Republic.
  • Epidemic Kaposi's sarcoma (KS) is one of the most frequent types of cancer in several African countries; however, very few data are available on human herpesvirus 8 (HHV-8) markers in KS patients from Central Africa.
  • In a series of 36 AIDS-KS cases from Central African Republic, we showed, using a real-time PCR quantitative assay, the high frequency (82%) of detectable HHV-8 DNA in peripheral blood mononuclear cells (PBMCs).
  • [MeSH-major] AIDS-Related Opportunistic Infections / virology. Antibodies, Viral / blood. DNA, Viral / blood. Herpesvirus 8, Human / isolation & purification. Sarcoma, Kaposi / virology. Skin Neoplasms / virology. Viral Load
  • [MeSH-minor] Adolescent. Adult. Antigens, Viral / immunology. Central African Republic. Child. Female. HIV Infections. Humans. Leukocytes, Mononuclear / virology. Male. Middle Aged. Polymerase Chain Reaction. Skin / virology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 2000 Apr;38(4):1404-8 [10747115.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8782-7 [15574792.001]
  • [Cites] AIDS. 2000 Sep 8;14(13):1907-10 [10997393.001]
  • [Cites] AIDS. 2000 Sep 29;14(14):2109-16 [11061651.001]
  • [Cites] Virology. 2000 Dec 5;278(1):60-74 [11112482.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(28):1-4 [11158199.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):517-34 [11313009.001]
  • [Cites] J Med Virol. 2002 Feb;66(2):235-40 [11782933.001]
  • [Cites] Lancet Infect Dis. 2002 May;2(5):281-92 [12062994.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 4;94(17):1333-5 [12208899.001]
  • [Cites] J Med Virol. 2002 Nov;68(3):399-403 [12226828.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):1-3 [12556950.001]
  • [Cites] Clin Infect Dis. 2003 May 1;36(9):1144-51 [12715309.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):502-4 [12888820.001]
  • [Cites] AIDS. 2003 Aug 15;17(12):1717-30 [12891058.001]
  • [Cites] AIDS. 2003 Aug 15;17(12):1847-51 [12891072.001]
  • [Cites] J Med Virol. 2004 Mar;72(3):358-62 [14748058.001]
  • [Cites] AIDS. 2004 Feb 20;18(3):485-93 [15090801.001]
  • [Cites] J Infect Dis. 2004 Sep 15;190(6):1068-75 [15319855.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] J Clin Microbiol. 1998 Aug;36(8):2220-2 [9665995.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):189-92 [10188717.001]
  • [Cites] J Hum Virol. 1998 Mar-Apr;1(3):193-9 [10195242.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1241-2 [10523163.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2069-73 [10979949.001]
  • (PMID = 16145154.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antigens, Viral; 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC1234088
  •  go-up   go-down


98. Lin CY, Chen MY, Hsieh SM, Sheng WH, Sun HY, Lo YC, Hung CC, Chang SC: Kaposi's sarcoma in patients with human immunodeficiency virus infection in Taiwan. J Microbiol Immunol Infect; 2009 Jun;42(3):227-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma in patients with human immunodeficiency virus infection in Taiwan.
  • BACKGROUND AND PURPOSE: Kaposi's sarcoma (KS) continues to occur in patients with human immunodeficiency virus (HIV) infection in the era of highly active antiretroviral therapy (HAART), and remains the most common HIV-associated malignancy.
  • This retrospective study was conducted to describe the change in incidence and characteristics of HIV-associated KS in Taiwan.
  • METHODS: The medical records of patients with HIV infection who received a diagnosis of KS at the National Taiwan University Hospital between June 1994 and March 2008 were reviewed.
  • RESULTS: During the 14-year study period, 62 HIV-infected patients were diagnosed with KS, which included 40 definite diagnoses (64.5%) by pathology and 22 probable diagnoses (35.5%) ascertained by characteristic lesions, compatible clinical manifestations, and response to treatment.
  • At the time of diagnosis of KS, the median CD4 count was 20 cells/microL (range, 1-371 cells/microL).
  • A considerable decline in the incidence of KS in HIV-infected patients since the introduction of HAART was demonstrated; in the pre-HAART era, 18 of 175 patients (10.3%; 95% confidence interval [CI], 6.53- 15.75) developed KS, compared with 44 of 1615 patients in the HAART era (2.7%; 95% CI, 2.03-3.65) [p < 0.0001].
  • The prognosis of HIV-infected patients with KS has improved since the introduction of HAART, as the mortality rate has declined from 77.8% in the pre-HAART era to 34.1% in the HAART era (p = 0.002).
  • CONCLUSIONS: The incidence of KS in HIV-infected patients and the mortality rate of these patients significantly declined in the HAART era, although KS continued to occur in patients with advanced HIV infection.
  • [MeSH-major] AIDS-Related Opportunistic Infections / pathology. HIV Infections / pathology. Sarcoma, Kaposi / virology


99. Uneda S, Murata S, Sonoki T, Matsuoka H, Nakakuma H: Successful treatment with liposomal doxorubicin for widespread Kaposi's sarcoma and human herpesvirus-8 related severe hemophagocytic syndrome in a patient with acquired immunodeficiency syndrome. Int J Hematol; 2009 Mar;89(2):195-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with liposomal doxorubicin for widespread Kaposi's sarcoma and human herpesvirus-8 related severe hemophagocytic syndrome in a patient with acquired immunodeficiency syndrome.
  • Hemophagocytic syndrome (HPS) sometimes occurres in patients with acquired immunodeficiency syndrome (AIDS).
  • Human herpesvirus-8 (HHV-8)/Kaposi's sarcoma (KS)-associated herpesvirus has so far been recognized as a trigger of HPS in immunosuppressed subject.
  • We describe a 39-year-old man with AIDS who had widespread mucocutaneous and pulmonary KS and severe HPS.
  • No opportunistic infections or neoplasias were detected except for KS.
  • Liposomal doxorubicin suppressed not only the widespread KS tumors, but also HHV-8 viremia resulting in decreased HPS in this patient.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Doxorubicin / therapeutic use. Herpesvirus 8, Human. Lymphohistiocytosis, Hemophagocytic / drug therapy. Sarcoma, Kaposi / drug therapy

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Infect Agent Cancer. 2008 Jan 21;3:1 [18208585.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2445-51 [9667262.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):285-91 [12856221.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1040-52 [17265518.001]
  • [Cites] Oncologist. 2007 Jan;12(1):114-23 [17227906.001]
  • [Cites] Chest. 2000 Apr;117(4):1128-45 [10767252.001]
  • [Cites] Blood Rev. 2007 Sep;21(5):245-53 [17590250.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):1112-5 [11167749.001]
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2002 Jul-Aug;57(4):175-86 [12244338.001]
  • [Cites] J Infect. 1997 May;34(3):219-25 [9200029.001]
  • [Cites] Int J STD AIDS. 1997 Nov;8(11):709-12 [9363548.001]
  • [Cites] G Ital Nefrol. 2005 May-Jun;22(3):281-6 [16001371.001]
  • [Cites] Eur J Med Res. 1998 Oct 14;3(10):461-4 [9753702.001]
  • [Cites] Int J Hematol. 2007 Jul;86(1):58-65 [17675268.001]
  • [Cites] AIDS. 1998 May 7;12(7):F45-9 [9619797.001]
  • [Cites] Eur J Med Res. 1999 Mar 26;4(3):95-100 [10085275.001]
  • [Cites] Cancer. 1979 Sep;44(3):993-1002 [225008.001]
  • [Cites] HIV Clin Trials. 2001 Sep-Oct;2(5):429-37 [11673818.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1203-6 [15840696.001]
  • [Cites] Lancet Infect Dis. 2002 May;2(5):281-92 [12062994.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):653-9 [9053490.001]
  • [Cites] Lancet Oncol. 2007 Feb;8(2):167-76 [17267331.001]
  • [Cites] AIDS. 2000 May 26;14(8):913-9 [10853972.001]
  • [Cites] Transplantation. 2002 Jul 15;74(1):131-2 [12134112.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1993 Feb;15(1):92-8 [8447564.001]
  • [Cites] Cancer Res. 1992 Feb 15;52(4):891-6 [1737351.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4044-58 [10361101.001]
  • (PMID = 19130173.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


100. Tornesello ML, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, Ruocco V, Katongole-Mbidde E, Buonaguro L, Buonaguro FM: TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and Caucasian patients. Oncology; 2009;77(5):328-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and Caucasian patients.
  • OBJECTIVES: Several studies have examined the association of codon 72 polymorphism of the TP53 gene, encoding either arginine or proline, in several tumor types but none have investigated its role in Kaposi's sarcoma (KS) development.
  • METHODS: In this prevalent case-control study, 67 cutaneous lesions of classic, iatrogenic, endemic as well as epidemic KS from African (n = 22) and Caucasian (n = 45) patients, and blood samples from 150 healthy controls (n = 57 African, n = 93 Caucasian) have been analyzed for arginine and proline allele distribution.
  • No significant differences in arginine and proline allele distribution were observed when the cases were stratified by HIV status/tumor type.
  • CONCLUSIONS: The results obtained in this study suggest that p53 polymorphism at codon 72 does not represent a risk factor for the development of all forms of KS, either among African or among Caucasian populations.
  • [MeSH-major] African Continental Ancestry Group / genetics. Codon. European Continental Ancestry Group / genetics. Genes, p53. Polymorphism, Genetic. Sarcoma, Kaposi / ethnology. Sarcoma, Kaposi / genetics
  • [MeSH-minor] Adult. Aged. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19940524.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Codon
  •  go-up   go-down






Advertisement